DOI: https://doi.org/10.30841/2307-5112.1-2.2020.204388

Коронавирусная болезнь: новый вызов человечеству и известные подходы к лечению

Л. В. Хіміон

Аннотация


В статье представлено обзор современных научных данных о плейотропных эффектах азитромицина и возможностей его применения в комплексной терапии коронавирусной болезни.

Ключевые слова


коронавирусная болезнь; SARS-CoV-2; азитомицин; гидроксихлорохин

Полный текст:

PDF (Українська)

Литература


Andreani J, Le Bideau M, Duflot I. In vitro testing of Hydroxychloroquine and Azithromycin on SARS-CoV-2 shows synergistic effect. https://www.mediterranee-infection.com/wp-content/uploads/2020/03/La-Scola-et-al-V1.pdf. 2020. [Preprint].

Andrew A. Lover. Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial. medRxiv 2020.03.22.20040949. 2020 [Preprint]

Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1cells/ Banjanac M, Munić Kos V., Nujić K. et al // Pharmacol Res. 2012 Oct;66(4):357-62. doi: 10.1016/j.phrs.2012.06.011. Epub 2012 Jul 3.

Azithromycin augments rhinovirusinduced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation / Menzel M., Akbarshahi H., Tufvesson E. et al. Oncotarget.- 2017, May 9;8(19):31601-31611. doi: 10.18632/oncotarget.16364.

Azithromycin Binding to the SARSCoV-2 Spike (S)Protein – ACE2 Complex. ChemRxiv. https://doi.org/10.26434/chemrxiv.12015792.v2. 2020. [Preprint].

Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind-placebo-controlled trial. / Brusselle GG, Vanderstichele C, Jordens P, et al. // Thorax. 2013;68:322–9. doi: 10.1136/thoraxjnl-2012-202698.

Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients // Menzel M., Akbarshahi H., Bjermer L. et al., Sci Rep. 2016. – 6: 28698. Published online 2016 Jun 28. doi: 10.1038/srep28698

Azithromycin can prolong QT interval and suppress ventricular contraction, but will not induce torsade de pointes / Ohara H, Nakamura Y, Watanabe Y. et al.// Cardiovasc Toxicol. 2015;15(3):232-40.

Blood, Tissue, and Intracellular Concentrations of Azithromycin during and after End of Therapy / Matzneller P., Krasniqi S., Kinzig M. et al.// Antimicrobial Agents and Chemotherapy p. 1736–1742 April 2013 Vol. 57, N 4.

Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Drug Saf. 2018;41(10):919-931.

Cardiovascular complications of severe acute respiratory syndrome / Yu C.M., Wong R.S., Wu E.B. et al.// Postgrad Med J 2006;82(964):140-4.

Choi Y, Lim HS, Chung D, Choi JG, Yoon D. Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice. Biomed Res Int. 2018;2018:1574806.

Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol. 2011;7(9):1153-67.

Clinical and antimicrobial effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day followup : an observational study. / Gautret P., Lagier J.C., Parola P. et al.// Travel Med Infect Dis. 2020AprAA:101663

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. World Health Organization. Available at https://www.who.int/publications-detail/clinicalmanagement-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected. 2020 Mar 13

Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France. / Million M, Lagier JC, Gautret P, et al. // https://www.mediterranee-infection.com/wp-content/uploads/2020/04/MS.pdf 2020 [Preprint]

Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. / Sagara I, Oduro AR, Mulenga M. et al. // Malar J. 2014;13:458.

Giudicessi J, Ackerman M. Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused ? Cleve Clin J Med. 2013;80(9):539-44.

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial / Gauret P., Lagier J.S., Parola P. et al.// Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print]

Hydroxychloroquine-Azithromycin and COVID-19/ Gautret P., Lagier J.S., Parola P. et al. // Available at https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf. 2020 Mar 30.

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 // Adarsh Bhimraj, Rebecca L. Morgan, Shumaker A.H. et al., Published by IDSA, 4/11/2020.

Ming Zhao. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies // Int J Antimicrob Agents.- 2020 Apr 16: 105982 doi: 10.1016/j.ijantimicag.2020.105982 [Epub ahead of print]

New treatment regimes for virus-induced exacerbations of asthma / Edwards MR, Kebadze T, Johnson MW et al. // Pulm Pharmacol Ther. 2006;19:320–34.

Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells / Schogler A., Korpf B.S., Edwards M.R. et al.// Eur Respir J 2015; 45: 428–439.

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 // Barlow A.; Landolf K.M.; Barlow B. et al., Pharmacotherapy. 2020; (ISSN: 1875-9114)

Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak// J Autoimmun. 2020, 109: 102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26.

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use of COVID-19: a multinational, network cohort and self-controlled series study / Lane J, Weaver J, Kostka K. et al. // medRxiv 2020.04.08.20054551. 2020 [Preprint]

Simpson TF, Kovacs RJ, Stecker EC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. American College of Cardiology; Cardiology Magazine. Available at https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquineazithromycin-treatment-for-covid-19. 2020 Mar 29.

The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future / Jin-Yan Li, Zhi You, Qiong Wang at al. // Microbes Infect .- 2020, Mar 22(2).- p. 80-85.

The Immunomodulatory Effects of Macrolides A Systematic Review of the Underlying Mechanisms/ Zimmermann P., Ziesenitz V.C., Curtis N., Ritz N. // Front. Immunol., 13 March 2018 | https://doi.org/10.3389/fimmu.2018.00302

The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin / Chorin E, Dai M, Shulman E. et al. // medRxiv 2020.04.02.20047050. 2020 [Preprint]

Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020mar18. pii:ehaa231.

Yu Chen, Quanium Liu, Deyin Guo. Emerging coronaviruses: Genome structure, replication, and pathogenesis // J Med Virol. 2020 Apr; 92(4): 418–423. Published online 2020 Feb 7. doi: 10.1002/jmv.25681




Copyright (c) 2020 Л. В. Хіміон

Creative Commons License
Эта работа лицензирована Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-8708 (Online), ISSN 2307-5112 (Print)

Flag Counter